Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s ...

Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied ...

Shares of Moderna, Inc. (NASDAQ:MRNA) are trading lower Monday following reports suggesting tighter controls on how vaccines gain approval.

The shares trade with liquidity of less than $1 million per day, while Schott AG retains a 77% stake. RBC applied a 9x 2027E EBITDA multiple, incorporating a 15% liquidity discount and 10% discount ...

The memo, written by FDA chief medical and scientific officer Vinay Prasad, reviewed 96 pediatric deaths and concluded that ...

Major U.S. equities indexes lost ground Monday afternoon, as shares of tech and cryptocurrency-related companies pulled back.

Piper Sandler 37th Annual Healthcare Conference December 2, 2025 11:00 AM ESTCompany ParticipantsJames Mock - Chief ...

The long-anticipated merger between Germany's leading mRNA developers is now official. BioNTech SE announced late Wednesday ...

Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become ...

The Dow fell on the stock market today. Moderna skidded after an FDA memo linked Covid vaccines to deaths. A gold stock ...

Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including the stock hit vaccine ...